Evidence map›Paper›PMID 38915481›Full record

ArticlebioRxiv : the preprint server for biology2024

Mutual information for detecting multi-class biomarkers when integrating multiple bulk or single-cell transcriptomic studies.

Jian Zou, Zheqi Li, Neil Carleton, Steffi Oesterreich, Adrian V Lee, George C Tseng

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Jian ZouDepartment of Statistics, School of Public Health, Chongqing Medical University, Chongqing, 400016, Chongqing, China.
Zheqi LiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, 02215, Massachusetts, USA.ORCID 0000-0003-1213-640X
Neil CarletonWomen's Cancer Research Center, UPMC Hillman Cancer Center (HCC), Pittsburgh, 15232, Pennsylvania, USA.
Steffi OesterreichWomen's Cancer Research Center, UPMC Hillman Cancer Center (HCC), Pittsburgh, 15232, Pennsylvania, USA.
Adrian V LeeWomen's Cancer Research Center, UPMC Hillman Cancer Center (HCC), Pittsburgh, 15232, Pennsylvania, USA.ORCID 0000-0001-9917-514X
George C TsengDepartment of Biostatistics, University of Pittsburgh, Pittsburgh, 15213, Pennsylvania, USA.ORCID 0000-0002-5447-1014

Funding

Mechanism-based strategies to target ER-mutant endocrine resistant breast cancerR01CA221303 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI OESTERREICH, STEFFI · 2018 to 2022
$2.0M
Disease subtyping guided by clinical phenotype for precision medicineR01LM014142 · NLM · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI George C. Tseng · 2023 to 2026
$1.2M
High-Throughput Computing for Genomics and Bioinformatics ResearchS10OD028483 · OD · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LEE, ADRIAN V · 2021 to 2021
$574k
Promotion of ER+ Breast Cancer Progression in the ElderlyF30CA264963 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CARLETON, NEIL · 2021 to 2025
$243k
NCI NIH HHS F30 CA264963NCI NIH HHS R01 CA221303NIH HHS S10 OD028483NLM NIH HHS R01 LM014142
6 · The paper itself

Abstract

Motivation: Biomarker detection plays a pivotal role in biomedical research. Integrating omics studies from multiple cohorts can enhance statistical power, accuracy and robustness of the detection results. However, existing methods for horizontally combining omics studies are mostly designed for two-class scenarios (e.g., cases versus controls) and are not directly applicable for studies with multi-class design (e.g., samples from multiple disease subtypes, treatments, tissues, or cell types). Results: We propose a statistical framework, namely Mutual Information Concordance Analysis (MICA), to detect biomarkers with concordant multi-class expression pattern across multiple omics studies from an information theoretic perspective. Our approach first detects biomarkers with concordant multi-class patterns across partial or all of the omics studies using a global test by mutual information. A post hoc analysis is then performed for each detected biomarkers and identify studies with concordant pattern. Extensive simulations demonstrate improved accuracy and successful false discovery rate control of MICA compared to an existing MCC method. The method is then applied to two practical scenarios: four tissues of mouse metabolism-related transcriptomic studies, and three sources of estrogen treatment expression profiles. Detected biomarkers by MICA show intriguing biological insights and functional annotations. Additionally, we implemented MICA for single-cell RNA-Seq data for tumor progression biomarkers, highlighting critical roles of ribosomal function in the tumor microenvironment of triple-negative breast cancer and underscoring the potential of MICA for detecting novel therapeutic targets. Availability: https://github.com/jianzou75/MICA.

Identifiers

PMID38915481
PMCPMC11195192

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.